Survodutide
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Survodutide
- bi 456906
- BI 456906
- BI 456906 (C-14)
- BI-456906
- bi456906
- BI456906
- l alaninamide l histidyl 1 aminocyclobutanecarbonyl l glutaminylglycyl l threonyl l phenylalanyl l threonyl l seryl l α aspartyl l tyrosyl l seryl l lysyl l tyrosyl l leucyl l α aspartyl l α glutamyl l arginyl l alanyl l alanyl l lysyl l α aspartyl l phenylalanyl l isoleucyl n6 n 17 carboxy 1 oxoheptadecyl l γ glutamylglycyl l serylglycyl l serylglycylglycyl l lysyl l tryptophyl l leucyl l α glutamyl l seryl
- l histidyl 1 aminocyclobutanecarbonyl l glutaminylglycyl l threonyl l phenylalanyl l threonyl l seryl l α aspartyl l tyrosyl l seryl l lysyl l tyrosyl l leucyl l α aspartyl l α glutamyl l arginyl l alanyl l alanyl l lysyl l α aspartyl l phenylalanyl l isoleucyl n6 n 17 carboxy 1 oxoheptadecyl l γ glutamylglycyl l serylglycyl l serylglycylglycyl l lysyl l tryptophyl l leucyl l α glutamyl l seryl l alaninamide
- L-Alaninamide, L-histidyl-1-aminocyclobutanecarbonyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-α-aspartyl-L-α-glutamyl-L-arginyl-L-alanyl-L-alanyl-L-lysyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-N6-[N-(17-carboxy-1-oxoheptadecyl)-L-γ-glutamylglycyl-L-serylglycyl-L-serylglycylglycyl]-L-lysyl-L-tryptophyl-L-leucyl-L-α-glutamyl-L-seryl-
- L-Histidyl-1-aminocyclobutanecarbonyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-α-aspartyl-L-α-glutamyl-L-arginyl-L-alanyl-L-alanyl-L-lysyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-N6-[N-(17-carboxy-1-oxoheptadecyl)-L-γ-glutamylglycyl-L-serylglycyl-L-serylglycylglycyl]-L-lysyl-L-tryptophyl-L-leucyl-L-α-glutamyl-L-seryl-L-alaninamide
- survodutida
- Survodutida
- survodutide
- Survodutide
- Survodutide (BI 456906)
- survodutide [INN]
- SURVODUTIDE [USAN]
- Survodutide [WHO-DD]
- survodutide inn
- survodutide usan
- survodutide who dd
- CAS registry numbers
- 2805997-46-8
- ChEMBL ID
- CHEMBL5314776
- FDA ingredient codes (UNII)
- 2ALA66NS64
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- survodutide
- Type
- Peptide
- Drug name stem
- -tide
- Action
- Agonist
- Action type
- Agonist
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 9.48
- Affinity units
- pEC50
- Action
- Agonist
- Action type
- Agonist
- Target
- glucagon receptor
- Gene symbol
- GCGR
- Protein identifier
- P47871
- Median affinity
- 9.28
- Affinity units
- pEC50
- Mechanism
- Glucagon receptor agonist
- Action type
- Agonist
- Target
- Glucagon receptor
- Protein identifier
- P47871
- Mechanism
- Glucagon-like peptide 1 receptor agonist
- Action type
- Agonist
- Target
- Glucagon-like peptide 1 receptor
- Protein identifier
- P43220
- Mechanism
- Glucagon receptor agonist
- Action type
- Agonist
- Target
- Glucagon receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
- Action type
- Agonist
- Target
- Glucagon-like peptide 1 receptor
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003095
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004285
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001249
- Highest recorded phase
- 3
- Condition identifier
- HP_0001394
- Highest recorded phase
- 1
- Condition identifier
- HP_0001395
- Highest recorded phase
- 3
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- HP_0025502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013209
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence I
- Type
- Protein
- Sequence
- HXQGTFTSDYSKYLDERAAKDFIKWLESA
- Component
- Sequence II
- Type
- Protein
- Sequence
- EGSGSGG
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTINCQASQSIYNNNELSWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCGGYKSYSNDGNGFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (41)
- A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
- A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood
- A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
- A Study in Healthy Men to Test How BI 1815368 is Processed in the Body
- A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body
- A Study in Healthy Men to Test How BI 456906 is Processed in the Body
- A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
- A Study in Healthy Men to Test How BI 764198 is Processed in the Body
- A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
- A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
- A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body
- A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body
- A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
- A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
- A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
- A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
- A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
- A Study to Test Different Doses of BI 456906 in Patients With Obesity
- A Study to Test How BI 1819479 is Taken up and Processed by the Body
In development for (5)
- Chronic kidney disease Phase 2
- Metabolic dysfunction-associated steatohepatitis Phase 3
- Metabolic dysfunction-associated steatotic liver disease Phase 1
- Obesity disorder Phase 1
- Type 2 diabetes mellitus Phase 3